Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: Does it have any clinical value?

Journal of Clinical Microbiology

Volumn 52, Issue 2, 2014, Pages 654-656

  Giménez, Estela ^a   Muñoz Cobo, Beatriz ^a   Solano, Carlos ^a   Amat, Paula ^a   Navarro, David ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS DNA;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS KINETICS; VIRUS LOAD;

ADOLESCENT; ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PLASMA; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; YOUNG ADULT;

EID: 84893154149     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02571-13     Document Type: Article

References (14)

1. Boeckh M, Ljungman P. 2009. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711-5719. http://dx.doi.org/10.1182/ blood-2008-10-143560.
2. Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, Potter M, Peggs K, Clark A, British Committee for Standards in Haematology, British Society of Blood and Marrow Transplantation, UK Virology Network. 2013. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br. J. Haematol. 162:25-39. http://dx.doi.org/10.1111/bjh. 12363.
3. Solano C, Navarro D. 2010. Clinical virology of cytomegalovirus infection following hematopoietic transplantation. Future Virol. 5:111-124. http://dx.doi.org/10.2217/fvl.09.64.
4. Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ, Furió S, Calabuig M, Tormo N, Navarro D. 2008. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J. Clin. Microbiol. 46:3311-3318. http://dx.doi.org/10.1128/JCM.00797-08.
5. Solano C, Muñoz-Cobo B, Giménez E, Remigia MJ, Amat P, Clari MA, Bravo D, Benet I, Montoro J, Navarro D. 2013. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center. Bone Marrow Transplant. 48:1010-1012. http://dx.doi.org/10.1038/ bmt.2012.286.
6. Muñoz-Cobo B, Solano C, Costa E, Bravo D, Clari MÁ, Benet I, Remigia MJ, Montoro J, Navarro D. 2011. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of activeCMVinfection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol. Blood Marrow Transplant. 17: 1602-1611. http://dx.doi.org/10.1016/j.bbmt.2011.08.014.
7. Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A, Corey L, Boeckh M. 2012. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18:1687-1699. http://dx.doi.org/10.1016/j.bbmt.2012.05.015.
8. Waggoner J, Ho DY, Libiran P, Pinsky BA. 2012. Clinical significance of low cytomegalovirus DNA levels in human plasma. J. Clin. Microbiol. 50:2378-2383. http://dx.doi.org/10.1128/JCM.06800-11.
9. Tormo N, Solano C, Benet I, Nieto J, de la Cámara R, López J, Garcia-Noblejas A, Muñoz-Cobo B, Costa E, Clari MA, Hernández-Boluda JC, Remigia MJ, Navarro D. 2011. Reconstitution of CMV pp65 and IE-1-specific IFN-CD8(-) and CD4(-) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant. 46:1437-1443. http://dx.doi.org/10.1038/bmt.2010.330.
10. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. 2000. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:2032-2036. http://dx.doi.org/10.1016/S0140-6736(00)02350-3.
11. Clari MÁ, Bravo D, Costa E, Muñoz-Cobo B, Solano C, Remigia MJ, Giménez E, Benmarzouk-Hidalgo OJ, Pérez-Romero P, Navarro D. 2013. Comparison of the new Abbott Real Time CMV assay and the AbbottCMVPCR kit for the quantitation of plasma cytomegalovirus DNAemia. Diagn. Microbiol. Infect. Dis. 75:207-209. http://dx.doi.org/10.1016/j.diagmicrobio.2012.10.010.
12. Fryer JF, Heath AB, Anderson R, Minor PD, Collaborative Study Group. 2010. Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report 2010. WHO/ BS/10.2138. World Health Organization, Geneva, Switzerland.
13. Bravo D, Clari MÁ Costa E, Muñoz-Cobo B, Solano C, José Remigia M, Navarro D. 2011. Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available realtime PCR assays for quantitation of plasma cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. J. Clin. Microbiol. 49:2899-2904. http://dx.doi.org/10.1128/JCM.00785-11.
14. Zweig MH, Campbell G. 1993. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39:561-577.